Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-Label Repeat-Dose IV ANX005 in Warm Autoimmune Hemolytic Anemia
2020-003675-18Phase 2Completed
- Sponsor
- Annexon Biosciences
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tanruprubart in warm autoimmune hemolytic anemia (wAIHA) and autoimmune haemolytic anaemia (AIHA), sponsored by Annexon Biosciences. Primary endpoint: Treatment-emergent adverse events. Started Sep 2020; status: completed.
02
Drugs
tanruprubart
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)autoimmune haemolytic anaemia (AIHA)
Beyond the preview
Go deeper on 2020-003675-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003675-18.